{"id":"W4382023148","doi":"10.3390/curroncol30070454","title":"Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Capecitabine; Medicine; Internal medicine; Metastatic breast cancer; Aromatase inhibitor; Oncology; Breast cancer; Regimen; Clinical endpoint; Retrospective cohort study; Adverse effect; Progression-free survival; Aromatase; Cancer; Chemotherapy; Randomized controlled trial; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002396355,0.0004126524,0.0008883393,0.000256115,0.0002044821,0.00001705751,0.0001718346,0.0001229628,0.0005855737],"category_scores_gemma":[0.0001577611,0.000343721,0.0002072232,0.0007009887,0.0002999436,0.0001759603,0.0000798918,0.0003591822,0.0002632903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001112935,"about_ca_system_score_gemma":0.0006899988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001405237,"about_ca_topic_score_gemma":0.0001169205,"domain_scores_codex":[0.9977597,0.0001049404,0.0005094241,0.0006283141,0.0003084791,0.0006891476],"domain_scores_gemma":[0.9980164,0.0006077058,0.0002804621,0.000347742,0.0004387448,0.0003089824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0268594,0.002464007,0.001062938,0.0004560646,0.00124454,0.0001341075,0.004640814,0.0002130643,0.01662944,0.0003036404,0.05132169,0.8946703],"study_design_scores_gemma":[0.05414235,0.00805979,0.04107155,0.0008079985,0.0005320367,0.0004772035,0.001989034,0.001606755,0.01039722,0.002200853,0.8776526,0.001062599],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9219159,0.01789409,0.00192997,0.04048708,0.004600929,0.005384506,0.006936385,0.0006635886,0.0001875728],"genre_scores_gemma":[0.9418095,0.02428967,0.005696667,0.00333292,0.007666088,0.009291405,0.004945358,0.0004556479,0.00251279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8936077,"threshold_uncertainty_score":0.9999015,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0781724674039042,"score_gpt":0.4118370089856422,"score_spread":0.333664541581738,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}